MARINA KONOPLEVA to Antigens, CD19
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Antigens, CD19.
Connection Strength
0.166
-
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2023 10; 37(10):2006-2016.
Score: 0.045
-
PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv. 2022 12 14; 8(50):eadd6403.
Score: 0.042
-
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov; 9(11):e833-e843.
Score: 0.042
-
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.
Score: 0.037